Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00528879 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 915
- Enrollment target
NCT00528879 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 915 participants.
The verdict
NCT00528879, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 915 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone. The safety of this treatment will also be studied.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 915 participants |
| Start Date | 2007-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00528879
The ClinicalTrials.gov registry entry for NCT00528879 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 915 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00528879 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00528879 about?
NCT00528879 is a clinical study titled "A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone". The purpose of this clinical research study is to learn whether dapagliflozin can help reduce blood sugar levels in participants with Type 2 diabetes that is not well controlled on metformin alone. The safety of this treatment will also be studied.
What is the current status of trial NCT00528879?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 915 participants. The study started on 2007-09. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00528879?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT00528879?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.